Table 1. The metabolites in PLC8024 were putatively identified (CD133-positive versus CD133-negative).
| Metabolite | raw mass (m/z) | Possible assignments | Fold-change | P-value | Postulated annotation |
|---|---|---|---|---|---|
| 1 | 215.03281(i−)* | glucose | 1.96↑ | 1.08E−05 | glucose and glutamine anaplerosis |
| 2 | 147.0766(q + ) | glutamine | 2.04↑ | 6.3E−04 | |
| 145.0600(q−) | |||||
| 3 | 148.0605(q + ) | glutamate | 1.46↑ | 1.7E−03 | |
| 146.0439(q−) | |||||
| 4 | 175.1193(q + ) | L-Arginine | 1.65↑ | 4.97E−04 | amino acid metabolism |
| 5 | 306.07653(i−) | Glutathione | 1.70 ↑ | 3.74E−05 | low levels of reactive oxygen species |
| 308.0912(q + ) | |||||
| 306.0752(q−) | |||||
| 6 | 321.0509(q−) | Thymidine monophosphate | 2.65↑ | 3.19E−04 | DNA synthesis |
| 7 | 347.03988(i−) | Inosine 5′-monophosphate | 1.58 ↓ | 1.27E−02 | nucleotide synthesis |
| 8 | 498.28959(i−) | Taurodeoxycholic acid | Unique in CD133+ | 1.72E−03 | bile acid transportation |
| 9 | 516.3014(q+) | Taurocholic acid | 2.15↑ | 6.47E−05 | |
| 10 | 440.24617(i+) | Leukotriene E4 | Unique in CD133+ | 6.57E−04 | fatty acid biosynthesis |
| 11 | 227.20167(i−) | Myristic acid | 1.49↑ | 5.59E−04 | |
| 12 | 218.10340(i−) | Pantothenic Acid | 1.73↑ | 1.31Eh03 | Coenzyme-A synthesis |
| 13 | 162.1107(q+) | L-Carnitine | 1.30↑ | 1.22E−04 | fatty acid beta-oxidation |
| 14 | 204.1231(q+) | Acetylcarnitine | 1.38↑ | 1.44E−03 | |
| 15 | 300.04910(i−) | N-Acetyl-D-glucosamine 6-phosphate/ N-Acetyl-D-glucosamine 1-phosphate | 3.89↑ | 5.0E−02 | hexosamine biosynthesis |
| 16 | 606.07451(i−) | Uridine diphosphate-N-acetylglucosamine | 4.50↑ | 1.2E−04 | |
| 17 | 399.14444(i+) | S-Adenosyl-L-methionine | 1.67↑ | 8.10E−03 | hypermethylation |
| 18 | 261.10833(i+) | L-alpha-glutamyl-L-hydroxyproline | 1.64↓ | 3.31E−03 | Prolyl hydroxylase might be inhibited |
| 19 | 132.0768(q+) | Creatine | 1.62↑ | 7.31E−04 | helps to supply energy |
| 20 | 245.04318(i−) | Glycerophosphoglycerol | 1.53↑ | 0.002.67 | Lipid accumulation suggests lipogenesis with tumorigenesis, metastasis and stemness. |
| 21 | 258.1101(q+) | Glycerophosphocholine | 1.62↑ | 1.88E−03 | |
| 22 | 425.26622(i+) | 1-heptadecanoyl-glycero-3-phosphate | 2.06 ↑ | 8.79E−04 | |
| 23 | 518.3168(q+) | LysoPC(18:3) | 2.34↑ | 5.35E−05 | |
| 24 | 520.3338(q+) | LysoPC(18:2) | 1.85↑ | 4.15E−05 | |
| 25 | 524.3689(q+) | LysoPC(18:0) | 1.71↑ | 4.64E−05 | |
| 26 | 548.3801(q+) | LysoPC(20:2) | 2.44↑ | 1.19E−04 | |
| 27 | 648.3800(q+) | 1-Palmitoyl-2-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine | 2.34↑ | 6.59E−05 | |
| 28 | 650.3959(q+) | 1-Palmitoyl-2-(5-hydroxy-8-oxo-6-octenoyl)-sn-glycero-3-phosphatidylcholine | 2.38↑ | 9.97E−07 | |
| 29 | 702.4985(q+) | PC(18:2/12:0) | 2.76↑ | 4.065E−05 | |
| 30 | 764.5063(q+) | PC(22:6/13:0) | 1.74↑ | 3.29E−04 | |
| 31 | 766.5308(q+) | PC(20:5/15:0) | 1.86↑ | 8.61E−04 | |
| 32 | 780.5437(q+) | PC(22:4/14:1) | 1.76↑ | 9.68E−04 |
(i+): FTICRMS-ESI (+); (i−): FTICRMS-ESI (−); (q+): QTOFMS-ESI (+); (q−): QTOFMS-ESI (−).
*The mass was assigned to be [glucose+Cl]−; LysoPC: lysophosphatidylcholine; PC: phosphatidylcholine.